Spotlight – What's next in Nash
The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.
GSK gets the vaccine edge on Pfizer
US experts favour GSK’s RSV vaccine over Pfizer’s, but both could be on the market soon.
Asco-GU – Talzenna remains a wait-and-see story in prostate cancer
Talapro-2 data backing Talzenna in all-comers are slated by Asco-GU’s discussant, as Lynparza shows precisely what might go wrong.
The next big tests for Argenx and its followers
Some believe that blocking FcRn has TNF-like potential, and J&J, Immunovant and UCB are all hot on Argenx’s heels.
Argenx's big bid to stay ahead
A crucial pivotal readout is approaching for the Belgian developer and Vyvgart, in a rare disease that represents the group’s riskiest move yet.
